Intellipharmaceutics International Inc. and Par Pharmaceutical, Inc. have added the development and commercialization of additional strengths of generic Focalin XR (dexmethylphenidate hydrochloride) for the U.S. market to their existing agreement, which includes 5, 10, 15 and 20mg strengths of generic Focalin XR. Intellipharmaceutics will receive an immediate cash payment from Par and will continue to receive a share of sales profits. Focalin XR is used in the treatment of Attention Deficit Hyp...